Mucin core polypeptide expression in the progression of neoplasia in Barrett's esophagus.

[1]  A. Hölscher,et al.  MUC1 and Nuclear β-Catenin Are Coexpressed at the Invasion Front of Colorectal Carcinomas and Are Both Correlated with Tumor Prognosis , 2004, Clinical Cancer Research.

[2]  M. Piazuelo,et al.  Phenotypic differences between esophageal and gastric intestinal metaplasia , 2004, Modern Pathology.

[3]  R. Odze,et al.  Mucin Core Peptide Expression Can Help Differentiate Barrett's Esophagus From Intestinal Metaplasia of the Stomach , 2003, The American journal of surgical pathology.

[4]  A. Hölscher,et al.  Immunoreactivity of cytokeratins (CK7, CK20) and mucin peptide core antigens (MUC1, MUC2, MUC5AC) in adenocarcinomas, normal and metaplastic tissues of the distal oesophagus, oesophago–gastric junction and proximal stomach , 2003, Histopathology.

[5]  Patricia L. Blount,et al.  Biomarkers in Barrett's esophagus. , 2003, Gastrointestinal endoscopy clinics of North America.

[6]  J. Goldblum,et al.  Barrett's Esophagus and Barrett's-Related Dysplasia , 2003, Modern Pathology.

[7]  J. Goldblum,et al.  p53 expression in low grade dysplasia in Barrett’s esophagus: correlation with interobserver agreement and disease progression , 2002 .

[8]  F. Sarkar,et al.  The Dichotomy in the Preinvasive Neoplasia to Invasive Carcinoma Sequence in the Pancreas: Differential Expression of MUC1 and MUC2 Supports the Existence of Two Separate Pathways of Carcinogenesis , 2002, Modern Pathology.

[9]  J. Dekker,et al.  Barrett's esophagus is characterized by expression of gastric-type mucins (MUC5AC, MUC6) and TFF peptides (TFF1 and TFF2), but the risk of carcinoma development may be indicated by the intestinal-type mucin, MUC2. , 2002, Human pathology.

[10]  J. Lüttges,et al.  The Mucin Profile of Noninvasive and Invasive Mucinous Cystic Neoplasms of the Pancreas , 2002, The American journal of surgical pathology.

[11]  S. Spechler,et al.  Clinical practice. Barrett's Esophagus. , 2002, The New England journal of medicine.

[12]  A. Dursun,et al.  Expression of MUC1 and MUC2 mucins in gastric carcinomas: their relationship with clinicopathologic parameters and prognosis. , 2002, Pathology, research and practice.

[13]  P. Blount,et al.  Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. , 2001 .

[14]  J. Triboulet,et al.  Mucin gene expression and cell differentiation in human normal, premalignant and malignant esophagus , 2000, International journal of cancer.

[15]  J. Jass,et al.  Mucin core proteins as differentiation markers in the gastrointestinal tract , 2000, Histopathology.

[16]  D. Alderson,et al.  Mucin gene expression in Barrett's oesophagus: an in situ hybridisation and immunohistochemical study , 2000, Gut.

[17]  A. Corfield,et al.  Mucins and mucosal protection in the gastrointestinal tract: new prospects for mucins in the pathology of gastrointestinal disease , 2000, Gut.

[18]  Patricia L. Blount,et al.  Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. , 2000 .

[19]  Mason,et al.  Expression of MUC1 and MUC2 mucin gene products in Barrett's metaplasia, dysplasia and adenocarcinoma: an immunopathological study with clinical correlation , 1999, Histopathology.

[20]  D. Olive,et al.  Differential MUC 1 expression in normal and neoplastic human pancreatic tissue. An immunohistochemical study of 60 samples. , 1999, American journal of clinical pathology.

[21]  B. Leggett,et al.  Ultrastructural Localization of Epithelial Mucin Core Proteins in Colorectal Tissues , 1999, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[22]  H. Barr,et al.  Apoptotic and proliferative activity in the neoplastic progression of Barrett's oesophagus: a comparative study , 1999, The Journal of pathology.

[23]  R. Goyal,et al.  Proliferative characteristics of intestinalized mucosa in the distal esophagus and gastroesophageal junction (short-segment Barrett's esophagus): a case control study. , 1999, Human pathology.

[24]  T. Irimura,et al.  Expression of sulfated carbohydrate chain and core peptides of mucin detected by monoclonal antibodies in Barrett's esophagus and esophageal adenocarcinoma , 1998, Journal of Gastroenterology.

[25]  R. Sampliner,et al.  Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus , 1998, American Journal of Gastroenterology.

[26]  G. Lauwers,et al.  Cellular kinetics in Barrett's epithelium carcinogenic sequence: roles of apoptosis, bcl-2 protein, and cellular proliferation. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[27]  Y. Kim,et al.  Mucin gene expression in normal, preneoplastic, and neoplastic human gastric epithelium. , 1995, Cancer research.

[28]  F. Real,et al.  Differential apomucin expression in normal and neoplastic human gastrointestinal tissues. , 1994, Gastroenterology.

[29]  D. Ota,et al.  MUC1 mucin expression as a marker of progression and metastasis of human colorectal carcinoma. , 1994, Gastroenterology.

[30]  M. Copin,et al.  Expression of human mucin genes in respiratory, digestive, and reproductive tracts ascertained by in situ hybridization. , 1993, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[31]  G Van Belle,et al.  Observer variation in the diagnosis of dysplasia in Barrett's esophagus. , 1988, Human pathology.